Upadacitinib Shows Long-Term Efficacy in Adolescent Atopic Dermatitis: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On December 11, 2024, we reported on findings from a study published in JAMA Dermatology that examined the long-term efficacy and safety of upadacitinib (Rinvoq; abbvie) in adolescents with moderate-to-severe atopic dermatitis (AD).

The study

Researchers assessed data from three phase 3 randomized clinical trials including 542 adolescents aged 12 to 17 years with moderate to severe AD.

In the Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318) trials, once-daily upadacitinib, 15 mg or 30 mg, adolescents were randomly assigned to receive once-daily upadacitinib 15 mg, 30 mg, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up) through 76 weeks.

The findings

• At week 76, Eczema Area and Severity Index Score (EASI-75) among participants who received upadacitinib 15 mg was achieved by 89.1%, 84.4%, and 87.8% in the Measure Up 1, Measure Up 2, and AD Up trials, respectively.

  • Among the 30 mg cohort in each trial, EASI-75 was achieved by 96.1%, 93.6%, and 82.7% of adolescents, with results having indicated maintenance or improvement in EASI-75 across 76 weeks, respectively.

• Achievement of efficacy measured by Validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 and Worst Pruritus Numerical Rating Scale improvement of 4 points or more from baseline were either maintained or improved through 76 weeks of upadacitinib 15 mg or 30 mg treatment.

Authors' comments

"In summary, these results through 76 weeks demonstrated that upadacitinib, with a favorable benefit-risk profile, was an effective long-term treatment option for adolescents with moderate to severe AD."

Click here for more details.